Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

ORYZON Announces New Senior VP of Clinical Development and Global Medical Affairs, Continuing its Expansion of US Corporate Activities

Globe Newswire - Tue Jan 11, 2022

MADRID, Spain and CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Dr. Ana Limón has been appointed as Senior Vice President of Clinical Development and Global Medical Affairs. This appointment strengthens Oryzon's permanent presence in the US as Oryzon builds out strategic partnerships with US hospitals and research institutions to develop its pipeline and clinical programs.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

Wall Street shares close up as megacap tech stocks rally

Why this money manager is venturing back into emerging markets and adding more U.S. tech

How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy

report on business

Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders

The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market

report on business

Fiera Capital’s largest shareholder looks to sell stake in company

The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide

The close: Stocks higher as investors digest earnings